MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Harrow Health Total Assets 2011-2026 | HROW
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Harrow Health
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 312 M | 157 M | 98.3 M | 57.5 M | 59.1 M | 49.5 M | 23.9 M | 27.2 M | 14.1 M | 10.2 M | 15.8 M | 10.7 M | 161 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 312 M | 161 K | 64.3 M |
Quarterly Total Assets Harrow Health
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 363 M | 345 M | 364 M | 389 M | 352 M | 307 M | 296 M | 312 M | 286 M | 224 M | 217 M | 157 M | 99 M | 98.1 M | 97.6 M | 98.3 M | 103 M | 107 M | 56.3 M | 57.5 M | 57.5 M | 57.5 M | 57.5 M | 59.1 M | 59.1 M | 59.1 M | 59.1 M | 49.5 M | 49.5 M | 49.5 M | 49.5 M | 23.9 M | 23.9 M | 23.9 M | 23.9 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 161 K | 161 K | 161 K | 161 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 389 M | 161 K | 90.6 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.2 | 1.27 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.68 | -0.56 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 13.92 | 5.86 % | $ 713 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.69 | 0.9 % | $ 402 M | Canada |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | $ 21.48 | -0.12 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
233 M | $ 5.72 | -3.3 % | $ 355 M | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 1.38 | 9.13 % | $ 24.1 M |  China |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.66 | -1.19 % | $ 3.37 M | Canada |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 7.9 | 3.41 % | $ 2.88 B | Canada |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 5.14 | 8.9 % | $ 72.3 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 4.32 | -0.92 % | $ 569 M | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 4.23 | -0.25 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 26.13 | 3.24 % | $ 1.21 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
9.65 B | $ 14.7 | -0.47 % | $ 2.02 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 0.95 | 2.85 % | $ 22.2 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 4.3 | 5.39 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
286 M | $ 9.35 | -1.86 % | $ 664 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 3.8 | - | $ 4.72 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 5.58 | 1.64 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
128 M | $ 0.64 | -0.12 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 8.95 | -3.35 % | $ 5.53 B | Canada |
 |
Veru
VERU
|
60.4 M | $ 2.34 | 0.43 % | $ 316 M | USA |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.0 | -2.0 % | $ 20.9 M | USA |
 |
Viatris
VTRS
|
50 B | $ 12.42 | 0.12 % | $ 15.1 B | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 1.11 | -3.91 % | $ 4.79 M | USA |
 |
Zomedica Corp.
ZOM
|
253 M | - | -0.21 % | $ 98 M | USA |